• Nippon Shinyaku signed an exclusive sublicense with Tanabe Pharma on October 22, 2026, to commercialize MT-2111 in Japan.
• The agreement covers loncastuximab tesirine-lpyl for relapsed or refractory diffuse large B-cell lymphoma.
• Tanabe Pharma filed for Japanese marketing authorization on October 29, 2026, targeting patients previously treated with at least two systemic therapies.
• Tanabe Pharma retains responsibility for ongoing development and obtaining Japanese regulatory approval under the current application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.